Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SENP2 | Q9HC62 | 18/20 | 0.49 |
| ▸ | SENP1 | Q9P0U3 | 18/20 | 0.49 |
| ▸ | SENP5 | Q96HI0 | 17/20 | 0.49 |
| ▸ | USP2 | O75604 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | RXRA | P19793 | 1/20 | 0.45 |
| ▸ | RXRB | P28702 | 1/20 | 0.45 |
| ▸ | RXRG | P48443 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4634974 | 0.88 | SENP5 (0.53) | SENP2SENP1SENP5USP2 | |
| SCHEMBL4633557 | 0.85 | CXCR2 (0.55) | SENP2SENP1SENP5ALDH1A1 | |
| SCHEMBL4632936 | 0.85 | ABCC1 (0.45) | SENP2SENP1SENP5USP2 | |
| SCHEMBL4605734 | 0.84 | SENP2 (0.53) | SENP2SENP1SENP5USP2KDM4E | |
| SCHEMBL4604177 | 0.81 | SENP2 (0.58) | SENP2SENP1SENP5USP2KDM4E | |
| SCHEMBL4604073 | 0.81 | SENP2 (0.58) | SENP2SENP1SENP5USP2KDM4E | |
| SCHEMBL4634988 | 0.80 | SENP2 (0.54) | SENP2SENP1SENP5USP2KDM4E | |
| SCHEMBL4634951 | 0.80 | KDM4E (0.67) | SENP2SENP1SENP5USP2KDM4E | |
| SCHEMBL4632950 | 0.79 | SENP5 (0.60) | SENP2SENP1SENP5USP2KDM4E | |
| SCHEMBL4604678 | 0.78 | SRD5A2 (0.46) | SENP2SENP1SENP5USP2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1685121-B1 | ANTIDIABETIC COMPOUNDS COMPRISING BENZOTHIOPHENE DERIVATIVES | MERCK PATENT GMBH (DE) | 2008-06-11 | — | — | EP | disclosed |
| US-7375130-B2 | Antidiabetic compounds comprising benzofuran and benzothiophene derivatives | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2008-05-20 | — | — | US | disclosed |
| US-20070078178-A1 | Antidiabetic compounds comprising benzofuran and benzothiophene derivatives | MERCK PATENT GMBH (DE) | 2007-04-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070078178-A1 | Antidiabetic compounds comprising benzofuran and benzothiophene derivatives | GPR119, INSR, GLP1R | SENP2 4091/4885SENP1 3148/4885SENP5 2840/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.